Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Peroneal electrical transcutaneous neuromodulation in the home treatment of the refractory overactive bladder

J. Krhut, M. Rejchrt, M. Slovak, RV. Dvorak, M. Grepl, P. Zvara

. 2023 ; 34 (6) : 1253-1260. [pub] 20220920

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu multicentrická studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23011325
E-zdroje Online Plný text

NLK ProQuest Central od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2010-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-01-01 do Před 1 rokem

INTRODUCTION AND HYPOTHESIS: The aim of this prospective, open-label, multicenter, noncomparative study was to evaluate the efficacy and safety of peroneal electrical transcutaneous neuromodulation (peroneal eTNM®) using the URIS® neuromodulation system as a home treatment for refractory overactive bladder (OAB). METHODS: The patients were treated with daily peroneal eTNM® for 30 min over a 6-week period. The primary endpoint was defined as the proportion of responders, i.e., participants with ≥ 50% reduction in the average daily sum of severe urgency episodes (defined as "I could not postpone voiding but had to rush to the toilet in order not to wet myself") and urgency incontinence episodes. In addition, bladder diary variables, symptom severity (OAB V8 questionnaire), treatment satisfaction (visual analog scale), and pain perception (visual analog scale) were evaluated at baseline (BL), at week 4 (W4), and at the end of treatment (EoT). Safety evaluations included monitoring of the incidence and severity of adverse events (AEs). Changes in time were analyzed using the nonparametric one-way ANOVA Friedman test for categorical variables and the Wilcoxon rank-sum test for the noncategorical variables. RESULTS: In total, 40 subjects were screened and 29 were included in the full analysis set. The proportion of responders was 86% at W4 and 79% at EoT. There was a significant reduction in frequency (p<0.001), number of severe urgency episodes (p< 0.001), number of urgency incontinence episodes (p=0.001), and number of nocturia episodes (p=0.002). There was a significant improvement in the OAB V8 score and treatment satisfaction (both p<0.001). Two mild treatment-related AEs were recorded. Both patients recovered without sequelae and completed the study. CONCLUSIONS: Peroneal eTNM® proved to be a highly effective and safe method for the home treatment of OAB, providing a therapeutic response in approximately 80% of patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011325
003      
CZ-PrNML
005      
20230801132951.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00192-022-05359-3 $2 doi
035    __
$a (PubMed)36125509
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Krhut, Jan $u Department of Urology, University Hospital, Tř. 17. Listopadu 1790, 708 52, Ostrava, Czech Republic. jan.krhut@fno.cz $u Department of Surgical Studies, Medical Faculty, Ostrava University, Ostrava, Czech Republic. jan.krhut@fno.cz $1 https://orcid.org/0000000342055926 $7 mzk2005309234
245    10
$a Peroneal electrical transcutaneous neuromodulation in the home treatment of the refractory overactive bladder / $c J. Krhut, M. Rejchrt, M. Slovak, RV. Dvorak, M. Grepl, P. Zvara
520    9_
$a INTRODUCTION AND HYPOTHESIS: The aim of this prospective, open-label, multicenter, noncomparative study was to evaluate the efficacy and safety of peroneal electrical transcutaneous neuromodulation (peroneal eTNM®) using the URIS® neuromodulation system as a home treatment for refractory overactive bladder (OAB). METHODS: The patients were treated with daily peroneal eTNM® for 30 min over a 6-week period. The primary endpoint was defined as the proportion of responders, i.e., participants with ≥ 50% reduction in the average daily sum of severe urgency episodes (defined as "I could not postpone voiding but had to rush to the toilet in order not to wet myself") and urgency incontinence episodes. In addition, bladder diary variables, symptom severity (OAB V8 questionnaire), treatment satisfaction (visual analog scale), and pain perception (visual analog scale) were evaluated at baseline (BL), at week 4 (W4), and at the end of treatment (EoT). Safety evaluations included monitoring of the incidence and severity of adverse events (AEs). Changes in time were analyzed using the nonparametric one-way ANOVA Friedman test for categorical variables and the Wilcoxon rank-sum test for the noncategorical variables. RESULTS: In total, 40 subjects were screened and 29 were included in the full analysis set. The proportion of responders was 86% at W4 and 79% at EoT. There was a significant reduction in frequency (p<0.001), number of severe urgency episodes (p< 0.001), number of urgency incontinence episodes (p=0.001), and number of nocturia episodes (p=0.002). There was a significant improvement in the OAB V8 score and treatment satisfaction (both p<0.001). Two mild treatment-related AEs were recorded. Both patients recovered without sequelae and completed the study. CONCLUSIONS: Peroneal eTNM® proved to be a highly effective and safe method for the home treatment of OAB, providing a therapeutic response in approximately 80% of patients.
650    _2
$a lidé $7 D006801
650    12
$a hyperaktivní močový měchýř $x farmakoterapie $7 D053201
650    _2
$a prospektivní studie $7 D011446
650    _2
$a výsledek terapie $7 D016896
650    12
$a inkontinence moči $7 D014549
650    _2
$a močení $x fyziologie $7 D014554
655    _2
$a multicentrická studie $7 D016448
655    _2
$a časopisecké články $7 D016428
700    1_
$a Rejchrt, Michal $u Department of Urology, 2nd Faculty of Medicine of Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Slovak, Martin $u STIMVIA®, Ostrava, Czech Republic
700    1_
$a Dvorak, Roman V $u STIMVIA®, Ostrava, Czech Republic
700    1_
$a Grepl, Michal $u Department of Urology, University Hospital, Tř. 17. Listopadu 1790, 708 52, Ostrava, Czech Republic $u Department of Surgical Studies, Medical Faculty, Ostrava University, Ostrava, Czech Republic
700    1_
$a Zvara, Peter $u Biomedical Laboratory and Research Unit of Urology, Department of Clinical Research, University of Southern Denmark, Odense, Denmark $u Department of Urology, Odense University Hospital, Odense, Denmark
773    0_
$w MED00002395 $t International urogynecology journal $x 1433-3023 $g Roč. 34, č. 6 (2023), s. 1253-1260
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36125509 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132948 $b ABA008
999    __
$a ok $b bmc $g 1963623 $s 1197590
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 34 $c 6 $d 1253-1260 $e 20220920 $i 1433-3023 $m International urogynecology journal $n Int. urogynecol. j. (Print) $x MED00002395
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...